Economic study of neutropenia induced by myelotoxic chemotherapy
- 1 July 1994
- journal article
- Published by Springer Science and Business Media LLC in Pharmacy World & Science
- Vol. 16 (4), 187-192
- https://doi.org/10.1007/bf01872867
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- [Economic evaluation of prophylaxis with recombinant granulopoiesis stimulating factor].1992
- Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating FactorNew England Journal of Medicine, 1992
- Recombinant Granulocyte Colony-Stimulating Factor (rG-CSF)PharmacoEconomics, 1992
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin DiseaseAnnals of Internal Medicine, 1992
- Single Daily Dose Ceftriaxone Plus Amikacin Treatment of Febrile Episodes in Neutropenic Patients Attending Day Hospital for Hematologic MalignanciesOncology, 1992
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- Ceftazidime Plus Amikacin Versus Ceftazidime Plus Vancomycin as Empiric Therapy in Febrile Neutropenic Children with CancerClinical Infectious Diseases, 1991
- Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University HospitalAmerican Journal Of Medicine, 1989
- Infection in cancer patients: A continuing associationAmerican Journal Of Medicine, 1986
- Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapyEuropean Journal of Cancer and Clinical Oncology, 1984